$584 Million is the total value of Novo Holdings A/S's 29 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 27.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INGN | INOGEN INC | $170,048,000 | -28.2% | 3,549,321 | 0.0% | 29.13% | -12.2% | |
| AAPL | APPLE INC | $59,976,000 | +13.2% | 267,788 | 0.0% | 10.28% | +38.4% | |
| CABO | CABLE ONE INC | $56,462,000 | +7.1% | 45,000 | 0.0% | 9.67% | +31.0% | |
| MIST | MILESTONE PHARMACEUTICALS INC | $49,879,000 | -31.3% | 2,674,470 | 0.0% | 8.54% | -16.0% | |
| MORF | MORPHIC HLDG INC | $47,909,000 | -8.6% | 2,645,446 | 0.0% | 8.21% | +11.7% | |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $24,598,000 | – | 2,445,147 | +100.0% | 4.21% | – |
| FOLD | AMICUS THERAPEUTICS INC | $18,589,000 | -35.7% | 2,317,870 | 0.0% | 3.18% | -21.4% | |
| SPNE | SEASPINE HLDGS CORP | $15,971,000 | -7.8% | 1,308,037 | 0.0% | 2.74% | +12.7% | |
| SIBN | SI BONE INC | $15,774,000 | -13.1% | 892,684 | 0.0% | 2.70% | +6.2% | |
| ETTX | ENTASIS THERAPEUTICS HLDGS I | $13,004,000 | -7.6% | 2,181,843 | 0.0% | 2.23% | +13.0% | |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $12,878,000 | -23.6% | 670,036 | +17.5% | 2.21% | -6.5% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $12,539,000 | -0.0% | 170,667 | +28.3% | 2.15% | +22.3% |
| AKBA | AKEBIA THERAPEUTICS INC | $12,152,000 | -19.0% | 3,100,000 | 0.0% | 2.08% | -1.0% | |
| INSP | INSPIRE MED SYS INC | $10,679,000 | +0.6% | 175,000 | 0.0% | 1.83% | +23.1% | |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $8,812,000 | -46.7% | 2,927,560 | -33.8% | 1.51% | -34.8% |
| SILK | Buy | SILK ROAD MEDICAL INC | $7,970,000 | +13.4% | 245,000 | +69.0% | 1.36% | +38.6% |
| Buy | FLEXION THERAPEUTICS INC | $6,170,000 | +141.8% | 450,000 | +116.9% | 1.06% | +195.3% | |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $5,754,000 | +1891.0% | 479,074 | +1904.4% | 0.99% | +2365.0% |
| KIDS | Sell | ORTHOPEDIATRICS CORP | $5,333,000 | -14.9% | 151,259 | -5.9% | 0.91% | +4.1% |
| STIM | Buy | NEURONETICS INC | $5,222,000 | -28.4% | 628,348 | +7.8% | 0.90% | -12.3% |
| SPRO | SPERO THERAPEUTICS INC | $4,939,000 | -7.9% | 465,983 | 0.0% | 0.85% | +12.6% | |
| XLRN | ACCELERON PHARMA INC | $4,730,000 | -3.8% | 119,708 | 0.0% | 0.81% | +17.6% | |
| XENT | Buy | INTERSECT ENT INC | $3,703,000 | +18.8% | 217,709 | +59.0% | 0.63% | +45.1% |
| VRNA | VERONA PHARMA PLCsponsored ads | $3,385,000 | -10.4% | 740,740 | 0.0% | 0.58% | +9.6% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $2,031,000 | -39.8% | 135,009 | 0.0% | 0.35% | -26.4% | |
| MYOK | New | MYOKARDIA INC | $1,583,000 | – | 30,348 | +100.0% | 0.27% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,498,000 | – | 35,900 | +100.0% | 0.26% | – |
| ZGNX | New | ZOGENIX INC | $1,429,000 | – | 35,700 | +100.0% | 0.24% | – |
| UMRX | UNUM THERAPEUTICS INC | $682,000 | -45.0% | 473,441 | 0.0% | 0.12% | -32.8% | |
| MRUS | Exit | MERUS N V | $0 | – | -495,016 | -100.0% | -1.02% | – |
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -3,446,564 | -100.0% | -1.17% | – | |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -97,481 | -100.0% | -1.76% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -300,000 | -100.0% | -3.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.